The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1229-1234.e4, December 2009

High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations

  • Lucie Blais, PhD

      Affiliations

    • Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada
    • Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada
    • Endowment Pharmaceutical Chair AstraZeneca in Respiratory Health, Montreal, Quebec, Canada
    • Corresponding Author InformationReprint requests: Lucie Blais, Université de Montréal, Faculté de pharmacie, CP 6128, succursale Centre-ville, Montréal (Québec), Canada H3C 3J7.
    • ,
  • Marie-France Beauchesne, PharmD

      Affiliations

    • Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada
    • Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada
    • Endowment Pharmaceutical Chair AstraZeneca in Respiratory Health, Montreal, Quebec, Canada
    • ,
  • Catherine Lemière, MD, MSc

      Affiliations

    • Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
    • Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada
    • ,
  • Naoual Elftouh, MSc

      Affiliations

    • Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada

Received 23 July 2009; received in revised form 16 September 2009; accepted 17 September 2009. published online 12 November 2009.

Full Text Available

  • Purchase this article for  31.50 USD

    Access is available for 24 hours.

    (Login or Register to purchase)

  • Subscribe to this title
  • Claim access now

    Current subscribers


    •  L.B. and C.L. are the recipients of a Salary Award from the Fonds de la recherche en santé du Québec (FRSQ).This study was funded through grants received from the FRSQ, the Canadian Institutes of Health Research, and the Canadian Foundation for Innovation. The research was completely independent from the funders.

     Disclosure of potential conflict of interest: L. Blais receives research support from AstraZeneca and Amgen. M.-F. Beauchesne receives honoraria for CE programs from AstraZeneca, GSK Canada, and BI/Pfizer Canada. C. Lemière receives research support from NIOSH and GlaxoSmithKline. The other author declares that she has no conflict of interest.

    PII: S0091-6749(09)01414-6

    doi:10.1016/j.jaci.2009.09.025

    The Journal of Allergy and Clinical Immunology
    Volume 124, Issue 6 , Pages 1229-1234.e4, December 2009